AMGN vs AZN vs GILD
161 measures in 16 categories, one definition each, computed from filings and market data.
AMGN67.3
Amgen Inc.
Healthcare · Drug Manufacturers - General
$432.49 −0.35%$233.8B mkt cap
Score DNA
AZN71.3
AstraZeneca PLC
Healthcare · Drug Manufacturers - General
$165.41 −0.76%$256.5B mkt cap
Score DNA
GILD43.8
Gilead Sciences, Inc.
Healthcare · Drug Manufacturers - General
$156.19 −0.75%$193.7B mkt cap
Score DNA
Price, rebased to 100 three years ago
AMGN AZN GILD · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | AMGN | AZN | GILD |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 1 | 0 |
| Insider $ bought, 180d | — | $0.00M | — |
| Congress purchases, 180d | 6 | 2 | 5 |
| Last Congress purchase | 2026-09-22 | 2026-03-31 | 2026-05-06 |
| 13F net change in holders | +19 | +156 | −32 |
| ETFs adding shares, 30d | 1,757 | 99 | 1,962 |
| ETFs trimming, 30d | 1,417 | 66 | 1,592 |
| Net ETF funds, 30d | +340 | +33 | +370 |
Valuation
16 measures| Measure | AMGN | AZN | GILD |
|---|---|---|---|
| P/E (TTM) | 26.7x
40th
|
24.6x
30th
|
— |
| PEG (P/E ÷ 3-yr EPS CAGR) | 10.09
100th
|
0.49
0th
|
— |
| Price / sales | 6.1x
64th
|
4.2x
36th
|
6.4x
82nd
|
| Price / book | 20.0x
90th
|
5.1x
30th
|
16.4x
80th
|
| Price / tangible book | — | — | — |
| Price / free cash flow | 23.0x
64th
|
26.2x
73rd
|
14.7x
27th
|
| Price / operating cash flow | 18.7x
73rd
|
18.6x
64th
|
14.3x
36th
|
| Enterprise value | $277.1B
45th
|
$283.8B
55th
|
$216.7B
27th
|
| EV / sales | 7.3x
82nd
|
4.6x
36th
|
7.1x
73rd
|
| EV / EBITDA | 15.7x
36th
|
13.7x
18th
|
162.5x
100th
|
| EV / EBIT | 21.4x
40th
|
19.8x
30th
|
— |
| EV / free cash flow | 27.2x
64th
|
29.0x
73rd
|
16.4x
18th
|
| Earnings yield | 3.7%
64th
|
4.1%
73rd
|
-1.7%
0th
|
| FCF yield | 4.4%
36th
|
3.8%
27th
|
6.8%
73rd
|
| Operating cash flow yield | 5.3%
27th
|
5.4%
36th
|
7.0%
64th
|
| Graham number (per share) | $88.14
78th
|
$69.65
56th
|
— |
Profitability (TTM)
12 measures| Measure | AMGN | AZN | GILD |
|---|---|---|---|
| Gross margin | 72.7%
55th
|
79.3%
82nd
|
79.6%
91st
|
| EBITDA margin | 46.2%
91st
|
33.7%
64th
|
4.4%
0th
|
| Operating margin | 33.2%
91st
|
22.8%
36th
|
-4.9%
0th
|
| EBIT margin | 34.0%
91st
|
23.3%
55th
|
-4.7%
0th
|
| Net margin | 22.9%
82nd
|
17.0%
55th
|
-10.6%
0th
|
| NOPAT margin | 28.2%
91st
|
18.9%
36th
|
-3.9%
0th
|
| FCF margin | 26.7%
64th
|
15.9%
9th
|
43.3%
100th
|
| Operating cash flow margin | 32.7%
73rd
|
22.5%
18th
|
44.5%
100th
|
| R&D / revenue | 20.0%
55th
|
24.6%
91st
|
19.9%
45th
|
| SG&A / revenue | 18.4%
27th
|
35.4%
100th
|
21.2%
45th
|
| Stock comp / revenue | 1.0%
27th
|
0.0%
0th
|
1.5%
91st
|
| Effective tax rate | 15.0%
18th
|
16.9%
36th
|
21.0%
64th
|
Returns on capital
11 measures| Measure | AMGN | AZN | GILD |
|---|---|---|---|
| ROE (on average equity) | 91.5%
90th
|
22.0%
40th
|
-20.6%
0th
|
| ROA | 9.5%
64th
|
9.2%
55th
|
-6.2%
0th
|
| ROIC | 19.5%
82nd
|
15.0%
45th
|
-3.4%
0th
|
| ROCE | 18.5%
73rd
|
17.0%
55th
|
-3.7%
0th
|
| Return on tangible assets | 14.1%
73rd
|
12.6%
55th
|
-2.7%
0th
|
| Cash ROIC (OCF / invested capital) | 22.7%
64th
|
17.8%
27th
|
38.8%
100th
|
| Gross profitability (GP / assets) | 29.0%
27th
|
43.4%
82nd
|
49.1%
100th
|
| ROIC, 3-yr average | 13.9%
73rd
|
11.0%
64th
|
3.5%
0th
|
| ROIC, 5-yr average | 21.5%
78th
|
9.0%
33rd
|
6.9%
0th
|
| ROE, 5-yr average | 121.3%
100th
|
13.7%
22nd
|
11.4%
11th
|
| Incremental ROIC | 95.6%
91st
|
96.6%
100th
|
94.2%
82nd
|
Growth
17 measures| Measure | AMGN | AZN | GILD |
|---|---|---|---|
| Revenue growth (TTM YoY) | 9.2%
82nd
|
8.6%
73rd
|
5.5%
55th
|
| Revenue growth (QoQ) | 16.7%
100th
|
0.6%
0th
|
12.1%
64th
|
| Revenue CAGR, 3 yr | 12.8%
91st
|
11.3%
82nd
|
3.6%
36th
|
| Revenue CAGR, 5 yr | 8.4%
73rd
|
15.8%
82nd
|
2.7%
36th
|
| Gross profit CAGR, 3 yr | 12.0%
82nd
|
13.1%
91st
|
3.7%
27th
|
| Operating income CAGR, 3 yr | 10.0%
50th
|
23.9%
90th
|
— |
| Net income growth (TTM YoY) | 32.1%
70th
|
25.9%
60th
|
— |
| Net income CAGR, 3 yr | 3.1%
50th
|
19.2%
90th
|
— |
| EPS growth (TTM YoY) | 31.4%
60th
|
151.7%
100th
|
— |
| EPS CAGR, 3 yr | 2.7%
50th
|
50.2%
90th
|
— |
| EPS CAGR, 5 yr | 10.0%
67th
|
36.2%
100th
|
— |
| FCF growth (TTM YoY) | -4.1%
30th
|
12.1%
70th
|
40.9%
90th
|
| FCF CAGR, 3 yr | 1.7%
18th
|
14.2%
73rd
|
13.9%
55th
|
| Operating cash flow CAGR, 3 yr | 4.9%
36th
|
10.7%
73rd
|
12.5%
82nd
|
| Book value CAGR, 3 yr | 19.4%
78th
|
39.0%
89th
|
-17.3%
0th
|
| Dividend CAGR, 3 yr | 1.6%
30th
|
25.5%
100th
|
1.3%
20th
|
| Sustainable growth rate | 36.2%
89th
|
11.7%
56th
|
— |
Margin history & stability
7 measures| Measure | AMGN | AZN | GILD |
|---|---|---|---|
| Gross margin, 3-yr average | 66.8%
27th
|
81.8%
91st
|
77.9%
82nd
|
| Operating margin, 3-yr average | 25.5%
73rd
|
20.4%
27th
|
10.7%
0th
|
| Net margin, 3-yr average | 17.3%
64th
|
14.9%
55th
|
5.0%
0th
|
| FCF margin, 3-yr average | 24.9%
64th
|
15.2%
27th
|
33.5%
100th
|
| Revenue stability (0-1) | 0.90
73rd
|
0.99
100th
|
0.88
64th
|
| Earnings stability (0-1) | 0.08
18th
|
0.68
91st
|
0.35
73rd
|
| Margin stability (0-1) | 0.92
27th
|
0.97
82nd
|
0.98
91st
|
Liquidity (latest quarter)
7 measures| Measure | AMGN | AZN | GILD |
|---|---|---|---|
| Cash & short-term investments | $14.0B
91st
|
$5.0B
27th
|
$3.2B
18th
|
| Net cash (− = net debt) | −$43.3B
36th
|
−$27.2B
73rd
|
−$23.1B
82nd
|
| Working capital | $9.5B
82nd
|
−$3.6B
18th
|
$2.9B
36th
|
| Current ratio | 1.37
73rd
|
0.89
18th
|
1.27
36th
|
| Quick ratio | 1.13
73rd
|
0.67
9th
|
1.09
55th
|
| Cash ratio (cash + ST investments / current liabilities) | 0.55
91st
|
0.16
0th
|
0.29
45th
|
| Defensive interval (days) | 587 days
100th
|
211 days
18th
|
117 days
0th
|
Leverage & solvency (latest quarter)
13 measures| Measure | AMGN | AZN | GILD |
|---|---|---|---|
| Total debt | $57.3B
82nd
|
$32.2B
27th
|
$26.2B
18th
|
| Debt / equity | 4.90
90th
|
0.64
20th
|
2.22
80th
|
| Net debt / equity | 3.71
90th
|
0.54
20th
|
1.95
80th
|
| Debt / assets | 59.9%
91st
|
27.8%
18th
|
53.2%
82nd
|
| Debt / capital | 83.1%
90th
|
39.1%
20th
|
68.9%
80th
|
| Debt / EBITDA | 3.25
45th
|
1.56
18th
|
19.67
100th
|
| Net debt / EBITDA | 2.46
45th
|
1.32
18th
|
17.29
100th
|
| Interest coverage (EBIT / interest) | 4.9x
45th
|
8.3x
64th
|
−1.4x
0th
|
| Cash interest coverage | 4.7x
9th
|
8.0x
36th
|
13.6x
73rd
|
| Debt payback (years of OCF) | 4.6 yrs
82nd
|
2.3 yrs
27th
|
1.9 yrs
0th
|
| Liabilities / assets | 87.8%
82nd
|
56.5%
9th
|
76.2%
73rd
|
| IS credit model rating | BB | AA- | BB+ |
| Implied credit spread (bps) | 475
73rd
|
100
18th
|
400
64th
|
Efficiency
11 measures| Measure | AMGN | AZN | GILD |
|---|---|---|---|
| Asset turnover | 0.42
18th
|
0.54
73rd
|
0.58
91st
|
| Fixed asset turnover | 4.46
55th
|
3.77
36th
|
5.22
82nd
|
| Inventory turnover | 1.6
18th
|
1.7
27th
|
3.3
82nd
|
| Receivables turnover | 4.0
0th
|
4.3
18th
|
6.2
100th
|
| Days sales outstanding | 91 days
100th
|
85 days
82nd
|
59 days
0th
|
| Days inventory outstanding | 224 days
82nd
|
220 days
73rd
|
111 days
18th
|
| Days payables outstanding | 404 days
82nd
|
769 days
100th
|
37 days
0th
|
| Cash conversion cycle (days) | −89 days
18th
|
−464 days
9th
|
133 days
73rd
|
| Capex / revenue | 6.0%
80th
|
6.6%
90th
|
1.2%
10th
|
| Capex / depreciation | 0.49
50th
|
0.63
70th
|
0.13
10th
|
| Operating expense ratio | 37.1%
27th
|
63.0%
82nd
|
213.0%
100th
|
Cash flow & earnings quality
7 measures| Measure | AMGN | AZN | GILD |
|---|---|---|---|
| Operating cash flow / net income | 1.43
40th
|
1.32
20th
|
— |
| FCF / net income | 1.16
30th
|
0.94
20th
|
— |
| FCF / operating cash flow | 81.5%
50th
|
70.8%
10th
|
97.4%
90th
|
| Capex / operating cash flow | 18.5%
50th
|
29.2%
90th
|
2.6%
10th
|
| Accruals ratio | -4.1%
55th
|
-2.9%
82nd
|
-32.0%
0th
|
| Sloan accruals ratio | -1.6%
73rd
|
-4.7%
27th
|
-6.4%
18th
|
| Earnings quality score (0-1) | 1.00
30th
|
1.00
30th
|
— |
Scores & forensic checks
15 measures| Measure | AMGN | AZN | GILD |
|---|---|---|---|
| IS score | 67
73rd
|
71
91st
|
44
9th
|
| IS profitability | 88
73rd
|
72
55th
|
20
0th
|
| IS growth | 74
82nd
|
65
73rd
|
37
36th
|
| IS value | 43
55th
|
45
64th
|
27
0th
|
| IS momentum | 91
82nd
|
90
73rd
|
38
0th
|
| IS risk (safety) | 50
9th
|
90
64th
|
80
55th
|
| IS quality | 69
36th
|
87
100th
|
32
0th
|
| IS balance sheet | 41
27th
|
59
91st
|
20
0th
|
| IS earnings quality | 67
27th
|
69
64th
|
26
0th
|
| IS cash flow | 68
55th
|
63
36th
|
78
91st
|
| Piotroski F-score (0-9) | 8
73rd
|
9
91st
|
5
18th
|
| Altman Z-score | 2.0
18th
|
3.8
82nd
|
3.2
55th
|
| Beneish M-score | −2.56
64th
|
−2.52
82nd
|
−4.14
0th
|
| Ohlson O-score | −6.96
82nd
|
−8.81
18th
|
−6.75
91st
|
| IS credit score | 44
27th
|
82
73rd
|
47
36th
|
Size (TTM)
8 measures| Measure | AMGN | AZN | GILD |
|---|---|---|---|
| Market cap | $233.8B
45th
|
$256.5B
55th
|
$193.7B
36th
|
| Revenue | $38.1B
27th
|
$61.4B
55th
|
$30.5B
18th
|
| EBITDA | $17.6B
55th
|
$20.7B
64th
|
$1.3B
9th
|
| Net income | $8.7B
55th
|
$10.4B
73rd
|
−$3.2B
0th
|
| Free cash flow | $10.2B
27th
|
$9.8B
18th
|
$13.2B
55th
|
| Total assets | $95.6B
36th
|
$115.7B
45th
|
$49.4B
18th
|
| Shareholders' equity | $11.7B
18th
|
$50.2B
82nd
|
$11.8B
27th
|
| Employees | 31,500
27th
|
96,100
91st
|
17,000
18th
|
Price performance
9 measures| Measure | AMGN | AZN | GILD |
|---|---|---|---|
| 1 day | −0.3% | −0.8% | −0.8% |
| 1 week | +4.2% | +3.9% | +3.3% |
| 1 month | +13.9% | −0.4% | +3.5% |
| 3 months | +19.5% | +1.2% | +17.2% |
| 6 months | +23.4% | −18.7% | +13.5% |
| Year to date | +34.7% | −8.8% | +28.4% |
| 1 year | +49.5% | −0.9% | +32.9% |
| 3 years, cumulative | +66.8% | +29.8% | +119.2% |
| 5 years, cumulative | +141.8% | +46.8% | +169.4% |
Technicals
4 measures| Measure | AMGN | AZN | GILD |
|---|---|---|---|
| RSI 14 | 62.5 | 56.2 | 63.5 |
| From 52-week high | −3.2% | −21.7% | −2.7% |
| From 52-week low | +54.3% | +8.5% | +37.9% |
| Beta | 0.41 | 0.21 | 0.33 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17